GSK Bio
NEWS
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
GlaxoSmithKline has voluntarily paused activities in its Phase III GRACE trial on a candidate maternal vaccine for respiratory syncytial virus.
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
As GSK moves into the new year, Chief Executive Officer Emma Walmsley predicted 2022 will be a “landmark year” for the company.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.
JOBS
IN THE PRESS